Can we stop AIDS with antiretroviral-based treatment as prevention?

Challenges to scaling up treatment as prevention (TasP) of HIV transmission are considerable in the developing-world context and include accessing at-risk populations, human resource shortages, adherence and retention in care, access to newer treatments, measurement of treatment effects, and long-te...

Descripción completa

Detalles Bibliográficos
Autores principales: Mills, Edward J, Nachega, Jean B, Ford, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Global Health: Science and Practice 2013
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168559/
https://www.ncbi.nlm.nih.gov/pubmed/25276515
http://dx.doi.org/10.9745/GHSP-D-12-00053
_version_ 1782335568421584896
author Mills, Edward J
Nachega, Jean B
Ford, Nathan
author_facet Mills, Edward J
Nachega, Jean B
Ford, Nathan
author_sort Mills, Edward J
collection PubMed
description Challenges to scaling up treatment as prevention (TasP) of HIV transmission are considerable in the developing-world context and include accessing at-risk populations, human resource shortages, adherence and retention in care, access to newer treatments, measurement of treatment effects, and long-term sustainable funding. Optimism about ending AIDS needs to be tempered by the realities of the logistic challenges of strengthening health systems in countries most affected and by balancing TasP with overall combination prevention approaches.
format Online
Article
Text
id pubmed-4168559
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Global Health: Science and Practice
record_format MEDLINE/PubMed
spelling pubmed-41685592014-09-30 Can we stop AIDS with antiretroviral-based treatment as prevention? Mills, Edward J Nachega, Jean B Ford, Nathan Glob Health Sci Pract Commentaries Challenges to scaling up treatment as prevention (TasP) of HIV transmission are considerable in the developing-world context and include accessing at-risk populations, human resource shortages, adherence and retention in care, access to newer treatments, measurement of treatment effects, and long-term sustainable funding. Optimism about ending AIDS needs to be tempered by the realities of the logistic challenges of strengthening health systems in countries most affected and by balancing TasP with overall combination prevention approaches. Global Health: Science and Practice 2013-03-21 /pmc/articles/PMC4168559/ /pubmed/25276515 http://dx.doi.org/10.9745/GHSP-D-12-00053 Text en © Mills et al. http://creativecommons.org/licenses/by/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly cited. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/
spellingShingle Commentaries
Mills, Edward J
Nachega, Jean B
Ford, Nathan
Can we stop AIDS with antiretroviral-based treatment as prevention?
title Can we stop AIDS with antiretroviral-based treatment as prevention?
title_full Can we stop AIDS with antiretroviral-based treatment as prevention?
title_fullStr Can we stop AIDS with antiretroviral-based treatment as prevention?
title_full_unstemmed Can we stop AIDS with antiretroviral-based treatment as prevention?
title_short Can we stop AIDS with antiretroviral-based treatment as prevention?
title_sort can we stop aids with antiretroviral-based treatment as prevention?
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4168559/
https://www.ncbi.nlm.nih.gov/pubmed/25276515
http://dx.doi.org/10.9745/GHSP-D-12-00053
work_keys_str_mv AT millsedwardj canwestopaidswithantiretroviralbasedtreatmentasprevention
AT nachegajeanb canwestopaidswithantiretroviralbasedtreatmentasprevention
AT fordnathan canwestopaidswithantiretroviralbasedtreatmentasprevention

Ejemplares similares